Melane Sampson, Author at BioTuesdays

Developments

Lipocine Completes Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression

Lipocine (NASDAQ: LPCN) has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). According to...

February 18, 2026

Developments

IP Australia grants Klotho 18 claims for s-KL

Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...

February 18, 2026

Feature

Imviva closing the gap between autologous and off-the-shelf CAR-T

Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...

February 17, 2026

Developments

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...

February 13, 2026

Developments

FDA clears Precision’s IND for PBGENE-DMD

Precision BioSciences (NASDAQ: DTIL) has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in...

February 13, 2026

Developments

BioSyent to acquire Oral Science

BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard...

February 10, 2026

Uncategorized

Arch scientists publish new data linking cytokine IL-32 to DKD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) announced a scientific team, led by principal scientist Dr. Justin Chun at the University of Calgary, report in the peer-reviewed journal Inflammation Research that...

February 9, 2026

Developments

PreveCeutical files patent for delivery of CNS-active agents

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF) has filed an international patent application for the delivery of CNS-active therapeutic agents covering methods and formulations aimed at addressing treatment challenges...

February 9, 2026

Executive Moves

Rita Johnson-Greene joins Ocugen as CFO

Ocugen (NASDAQ: OCGN) has appointed Rita Johnson-Greene as chief financial officer (CFO). Ms. Johnson-Greene brings more than 20 years of healthcare experience to the role. Most recently, she served as chief operating...

February 9, 2026

Developments

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Exicure (NASDAQ: XCUR) announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4...

February 6, 2026

Author - Melane Sampson

Lipocine Completes Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression

IP Australia grants Klotho 18 claims for s-KL

Imviva closing the gap between autologous and off-the-shelf CAR-T

Bioxytran reports positive Phase 2 data for ProLectin-M

FDA clears Precision’s IND for PBGENE-DMD

BioSyent to acquire Oral Science

Arch scientists publish new data linking cytokine IL-32 to DKD

PreveCeutical files patent for delivery of CNS-active agents

Rita Johnson-Greene joins Ocugen as CFO

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Subscribe